Scientific and Clinical Advisors & Collaborators
Pr. Antoine Andremont, MD, PhD 🇫🇷
Co-Founder and President of the Scientific Board
Prof. Antoine Andremont MD, PhD (France), is amongst the leading international experts of the consequences of antibiotics on the evolution of bacterial resistance and on the occurrence of healthcare-acquired infections. He is the author of over 250 international publications and has filed 5 patents dealing with mechanisms of resistance. Pr. Antoine Andremont has also been part of the WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) and the EU Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) as an expert and a scientific advisor. Primarily trained as a pediatrician and microbiologist, both in France and in the USA, he worked for 17 years at the Medical Microbiology Laboratory of the Gustave Roussy Institute, the most important French center for cancer research and treatment. He then directed the Bacteriology Laboratory of the Bichat-Claude Bernard Hospital Group for 25 years. Professor Andremont is the scientific founder of Da Volterra and benefiting from his expertise is a major success factor for Da Volterra.
Pr. Mark Wilcox, MD, FRCPath 🇬🇧
Prof. Mark Wilcox MD, (England), is the Lead on Clostridium difficile for Public Health England (PHE) and is the National Clinical Director for Infection Prevention and Control and Antimicrobial Resistance at NHS England. He is a Consultant Microbiologist and Infection Lead for the National Institutes of Health Research Leeds MIC at the Leeds Teaching Hospitals (LTHT), and Professor of Medical Microbiology at the University of Leeds (Leeds Institute of Medical Research). He has formerly been the Director of Infection Prevention, Infection Control Doctor and Clinical Director of Pathology at LTHT.
Pr. Maria J.G.T. Vehreschild, MD 🇩🇪
Prof. Maria J.G.T. Vehreschild, MD (Germany), is a specialist in internal medicine, infectious disease and hematology/oncology. Her clinical research focuses on approaches targeting the microbiome. She is the Head of the Department of Infectious Diseases at the University Hospital Frankfurt and is a leading provider of fecal microbiota transfers in Germany. She is the European coordinator of the MICROCARE Phase 3 study conducted by Da Volterra.
Pr. Yehuda Carmeli, MD, PhD 🇮🇱
Prof. Yehuda Carmeli MD, PhD (Israel), is the head of the National Institute for Antibiotic Resistance and Infection Control, at the Tel Aviv Medical Center.
Dr. Thomas J. Louie, MD 🇨🇦
Dr. Thomas J. Louie, MD (Canada), is a Clinical Professor of Medicine (Emeritus) in the departments of medicine and microbiology-immunology & infectious diseases at the University of Calgary in Alberta, Canada. Formerly head of the division of infectious diseases and formerly lead infection control physician in the Calgary health region, he continues to serve as an Infection Prevention & Control officer at Alberta Health Services and has been a long term clinical investigator on microbiome sparing antimicrobials for the treatment of Clostridioides difficile infection. He is also a pioneer in the use of fecal microbiota transplantation and has been an investigator in multiple FMT protocols. The main theme of research is hospital epidemiology, microbial ecology, antibiotic resistance, restoration of and role of the microbiome in health and disease.
Pr. Stephan Harbarth, MD 🇨🇭
Prof. Stephan Harbarth, MD (Switzerland), Chief of the Prevention Unit for Nosocomial Infections of the Geneva Hospital, is a distinguished infectious diseases specialist and hospital epidemiologist who has published more than 300 original articles in peer-reviewed journals. He is responsible for the STAT-NET project within COMBACTE-NET aiming at the implementation of innovative clinical development strategies.
Pr. Marc Bonten, MD, PhD 🇳🇱
Prof. Marc Bonten, MD, PhD (The Netherlands), is leading the research group of infectious Disease Epidemiology of the Julius Center of Health Sciences and Primary Care, at the UMC Utrecht, where he is professor of molecular epidemiology of infectious diseases. He is also the Scientific Director of the research theme “Tackling Antimicrobial Resistance” of the Netherlands Centre for One Health and the chairman of the focus area Infection & Immunity at the UMC Utrecht. Pr. Bonten has been the principal investigator of numerous large-scale epidemiological studies, he coordinates the COMBACTE-NET program with Da Volterra and co-coordinates the ECRAID (European Clinical Research Alliance on Infectious Diseases) plan with Pr. Herman Goossens.
Pr. Herman Goossens, MD 🇧🇪
Prof. Herman Goossens, MD (Belgium), is Professor of Microbiology at the University of Antwerp where he heads the Laboratory of Medical Microbiology. This laboratory is part of PREPARE, the European Union’s platform for European preparedness against emerging epidemics, and RECOVER, Rapid European COVID-19 Emergency Research response, both of which he is the coordinator. He is one of the major opinion leaders on antibiotic resistance in Europe and co-coordinates the ECRAID (European Clinical Research Alliance on Infectious Diseases) plan with Pr. Marc Bonten.
Pr. Oliver Cornely, MD, FACP, FIDSA, FAAM, FECMM 🇩🇪
Prof. Oliver Cornely is Director & Chair of Translational Research at the CECAD Institute of the University of Cologne, and Scientific Director of the Centre for Clinical Trials both located at the University Hospital of Cologne, Germany. He is board certified in internal medicine, infectious diseases, hematology, oncology, and emergency medicine, and holds degrees in medical mycology and travel medicine. Prof. Cornely is also a clinical infectious diseases consultant at the University Hospital of Cologne.
Pr. France Mentré, MD, PhD 🇫🇷
Prof. France Mentré, MD, PhD (France), is a biomedical expert in Public health and Pharmacology & Toxicology. Her research has focused on biostatistical modelling and pharmacometrics for more than 25 years. Since 2000, France Mentré is a Professor of Biostatistics at Paris University, School of Medicine.
Pr. Jennifer Dressman, PhD 🇩🇪
Prof. Jennifer Dressman, PhD recently retired from her position as Professor of Pharmaceutical Technology at J.W. Goethe University and is now collaborating with the Fraunhofer Institute of Translational Medicine and Pharmacology in Frankfurt. She is expert in predictive models for the delivery of drugs via the gastrointestinal tract. Specialist in gastroenterological physiology and drug delivery/absorption in the GI tract, Pr. Dressman advises Da Volterra on the development and testing of colonic drug delivery systems.
Dr. Renaud Buffet, MD 🇫🇷
Dr. Renaud Buffet, MD (France), is a researcher at the Saint-Louis Hospital (Paris, France) and a consultant in Translational and Clinical Research in Onco-hematology and Immunotherapy. He has more than 30 years of experience in the clinical development of products in transplantation, hemato-oncology and immuno-oncology, including 10 years at Innate Pharma.
Pr. Marcel R. M. van den Brink, MD, PhD 🇺🇸
Prof. Marcel van den Brink is a medical oncologist who performs both laboratory and clinical research related to allogeneic bone marrow transplantation (BMT) and immuno-oncology. He is the Head of the Division of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center (MSKCC) and holds a joint appointment in the Immunology and Transplantation Program of the Sloan Kettering Institute. He is the Co-Director of the Parker Institute for Cancer Immunotherapy at MSKCC and Chairman of the Board of DKMS, an international nonprofit organization devoted to bone marrow donor registration. As a clinical scientist, he is involved in immunotherapeutic trials of cytokines, cell therapies, as well as strategies to manipulate the intestinal microbiome for patients with hematologic malignancies. His laboratory is devoted to the immunology of BMT and he studies immune reconstitution, pathophysiology of graft-versus-host disease, the intestinal microbiota, and chimeric antigen receptor T cells in patients and preclinical models.
Pr. Gérard Zalcman, MD, PhD 🇫🇷
Prof. Gérard Zalcman MD, PhD (France), is the Head of the Thoracic Oncology Department of the Bichat Hospital, in Paris (Université de Paris) and joined the U830 INSERM laboratory, « Genetics & Biology of cancers » at the Research Centre of the Curie Institute. In Jan. 2021 he was nominated Medical Director of the University North-Paris Institute of Cancer, a joint venture of 6 public university hospitals from North Paris area (Bichat, Lariboisière, Saint-Louis, Beaujon, Louis Mourier, Robert Debré) dedicated to cancer care and research. He is a member of ESMO, ASCO, IASLC, EACR and European Respiratory Society. He authored or co-authored more than 250 peer-reviewed publications and he has been investigator of more than 50 phase I, II and III clinical trials during the last decade, in the field of lung cancer and mesothelioma.
Pr. Benjamin Besse, MD, PhD 🇫🇷
Prof. Benjamin Besse, MD (France), is Director of the Department of Cancer Medicine at the Gustave Roussy Institute and Chairman of the European Organisation for Research and Treatment of Cancer (EORTC) Scientific Chairs Council. He specializes in the management of thoracic cancers, particularly lung cancer, and has been involved in many clinical studies evaluating novel immunotherapies.
Pr. Hossein Borghaei, MD 🇺🇸
Prof. Hossein Borghaei, MD (USA), is Director of the Division of Thoracic Medical Oncology at the Fox Chase Cancer Center and Professor in the Department of Hematology/Oncology. He also co-directs the Immune Monitoring Facility. He is a specialist in the treatment of lung cancer.
Pr. Martin Reck, MD 🇩🇪
Prof. Martin Reck, MD (Germany), is Director of the Department of Thoracic Oncology and Clinical Trials at the Grosshansdorf Lung Clinic. He is also a senior researcher at the German Lung Research Center (DZL) in the field of lung cancer.
Pr. Tony Mok, MD 🇭🇰
Prof. Tony Mok, MD (Hong Kong), is Professor in the Department of Clinical Oncology at the Chinese University of Hong Kong, Prince of Wales Hospital. He is a specialist in the application of new therapeutic approaches in the treatment of lung cancer.
Pr. Enriqueta Felip, MD, PhD 🇪🇸
Prof. Enriqueta Felip is the Head of the Thoracic and Head and Neck Cancer Unit within the Oncology Department of Vall d’Hebron Hospital, Barcelona, Spain. She is in charge of thoracic malignancy management, and is responsible for thoracic cancer trials undertaken by the Oncology Department. She is currently a member of the scientific comitee of Spanish Lung Cancer Group (SLCG), member of ESMO, ASCO and IASLC and she is the Vice-President of the Spanish Society of Medical Oncology (SEOM). the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), and the International Association for the Study of Lung Cancer (IASLC). Prof. Felip is also author of many peer-reviewed articles and book chapters relating to the field of thoracic malignancies.
Ongoing Clinical Trials